Literature DB >> 22152171

Cost-effectiveness of the introduction of a pre-erythrocytic malaria vaccine into the expanded program on immunization in sub-Saharan Africa: analysis of uncertainties using a stochastic individual-based simulation model of Plasmodium falciparum malaria.

Nicolas Maire1, Samuel D Shillcutt, Damian G Walker, Fabrizio Tediosi, Thomas A Smith.   

Abstract

OBJECTIVE: To evaluate the cost-effectiveness of introducing the RTS,S malaria vaccine into the Expanded Programme on Immunization (EPI) in Sub-Saharan Africa (SSA), the contributions of different sources of uncertainty, and the associated expected value of perfect information (EVPI).
METHODS: Vaccination was simulated in populations of 100,000 people at 10 different entomological inoculation rates (EIRs), using an existing stochastic model and a 10-year time horizon. Incremental cost-effectiveness ratios (ICERs) and EVPI were computed from weighted averages of outputs using two different assignments of the EIR distribution in 2007. Uncertainty was evaluated by resampling of epidemiological, vaccination, and health systems model parameters.
RESULTS: Health benefits were predicted consistently only at low transmission, and program costs always substantially exceeded case management savings. Optimal cost-effectiveness was at EIR of about 10 infectious bites per annum (ibpa). Main contributors to ICER uncertainty were uncertainty in transmission intensity, price per vaccine dose, decay rate of the vaccine effect, degree of homogeneity in host response, and some epidemiological model parameters. Other health system costs were unimportant. With a ceiling ratio of 207 international dollars per disability-adjusted life-year averted, 52.4% of parameterizations predicted cost-effectiveness in the primary analysis.
CONCLUSIONS: Cost-effectiveness of RTS,S will be maximal in low endemicity settings (EIR 2-20 ibpa). Widespread deployment of other transmission-reducing interventions will thus improve cost-effectiveness, suggesting a selective introduction strategy. EVPI is substantial. Accrual of up-to-date information on local endemicity to guide deployment decisions would be highly efficient.
Copyright © 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22152171     DOI: 10.1016/j.jval.2011.06.004

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  17 in total

1.  Climate influences on the cost-effectiveness of vector-based interventions against malaria in elimination scenarios.

Authors:  Paul E Parham; Dyfrig A Hughes
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-04-05       Impact factor: 6.237

2.  Decision-making on malaria vaccine introduction: the role of cost-effectiveness analyses.

Authors:  Vasee S Moorthy; Raymond Hutubessy; Robert D Newman; Joachim Hombach
Journal:  Bull World Health Organ       Date:  2012-09-19       Impact factor: 9.408

3.  Comparative cost models of a liquid nitrogen vapor phase (LNVP) cold chain-distributed cryopreserved malaria vaccine vs. a conventional vaccine.

Authors:  Cristina Reyes Garcia; Fatuma Manzi; Fabrizio Tediosi; Stephen L Hoffman; Eric R James
Journal:  Vaccine       Date:  2012-11-10       Impact factor: 3.641

4.  Malaria vaccine: a step toward elimination.

Authors:  Harashish Jindal; Bhumika Bhatt; Jagbir S Malik; Shashikantha Sk; Bharti Mehta
Journal:  Hum Vaccin Immunother       Date:  2014-03-18       Impact factor: 3.452

5.  Ensemble modeling of the likely public health impact of a pre-erythrocytic malaria vaccine.

Authors:  Thomas Smith; Amanda Ross; Nicolas Maire; Nakul Chitnis; Alain Studer; Diggory Hardy; Alan Brooks; Melissa Penny; Marcel Tanner
Journal:  PLoS Med       Date:  2012-01-17       Impact factor: 11.069

6.  Importance of factors determining the effective lifetime of a mass, long-lasting, insecticidal net distribution: a sensitivity analysis.

Authors:  Olivier J T Briët; Diggory Hardy; Thomas A Smith
Journal:  Malar J       Date:  2012-01-13       Impact factor: 2.979

7.  Simulated impact of RTS,S/AS01 vaccination programs in the context of changing malaria transmission.

Authors:  Alan Brooks; Olivier J T Briët; Diggory Hardy; Richard Steketee; Thomas A Smith
Journal:  PLoS One       Date:  2012-03-06       Impact factor: 3.240

8.  The public health impact of malaria vaccine RTS,S in malaria endemic Africa: country-specific predictions using 18 month follow-up Phase III data and simulation models.

Authors:  Melissa A Penny; Katya Galactionova; Michael Tarantino; Marcel Tanner; Thomas A Smith
Journal:  BMC Med       Date:  2015-07-29       Impact factor: 8.775

9.  Defining the relationship between infection prevalence and clinical incidence of Plasmodium falciparum malaria.

Authors:  Ewan Cameron; Katherine E Battle; Samir Bhatt; Daniel J Weiss; Donal Bisanzio; Bonnie Mappin; Ursula Dalrymple; Simon I Hay; David L Smith; Jamie T Griffin; Edward A Wenger; Philip A Eckhoff; Thomas A Smith; Melissa A Penny; Peter W Gething
Journal:  Nat Commun       Date:  2015-09-08       Impact factor: 14.919

10.  Modeling the public health impact of malaria vaccines for developers and policymakers.

Authors:  Julia K Nunes; Vicky Cárdenas; Christian Loucq; Nicolas Maire; Thomas Smith; Craig Shaffer; Kårstein Måseide; Alan Brooks
Journal:  BMC Infect Dis       Date:  2013-07-01       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.